Jefferies Downgrades ResMed (RMD) to Underperform; AirSense10 Cycle Waning
- Wall Street opens flat as investors assess earnings
- General Motors (GM) Tops Q3 EPS by 28c
- Procter & Gamble (PG) Tops Q1 EPS by 5c
- DuPont (DD) Tops Q3 EPS by 14c; Boosts FY16 EPS Outlook; Says Continuing to Work with Regulators
- Pre-Open Stock Movers 10/25: (SAEX) (CWEI) (SWFT) Higher; (DPRX) (CRBP) (UA) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Jefferies downgraded ResMed (NYSE: RMD) from Hold to Underperform with a price target of $58.00 (from $60.00), saying the AirSense10 Cycle is waning.
Analyst Anthony Petrone commented, "We conducted a DME survey and several expert calls to gauge the latest CPAP trends. AirSense10 is still considered best-in-class, but Dream has closed the gap while being priced at a discount. Lower Medicare rates effective July 1, 2016 are pressuring private rates and are expected to lead to further DME consolidation and price pressure. Downgrading to UP as cycles evolve."
Shares of ResMed closed at $69.78 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- T-Mobile (TMUS) PT, Estimates Raised at Jefferies
- UBS Cuts Price Target on Kimberly-Clark (KMB) Following 3Q Report
- UBS Raises Price Target on Zions Bancorp (ZION) to $29 Following 3Q EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst PT Change, Downgrades, Hot Downgrades
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!